Zura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativa

Zura Bio launches global Phase 2 study of tibulizumab in HS - BioTuesdays

Zura Bio (NASDAQ:ZURA) announced that it has launched a global Phase 2 study—TibuSHIELD—to evaluate tibulizumab in 180 adults with moderate to severe hidradenitis suppurativa (HS) across Canada, the U.S. and Europe. According to Zura Bio, TibuSHIELD is the first study to evaluate the dual inhibition of a B-cell activating factor (BAFF) and interleukin-17A pathway in adults with HS. Topline results for the primary 16-week efficacy endpoint are ex…

Zura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativa

Zura Bio has launched the Phase II TibuSHIELD trial of tibulizumab for moderate to severe hidradenitis suppurativa (HS).The post Zura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativa appeared first on Clinical Trials Arena.